Business Context and Reporting Period
Company: HALOZYME THERAPEUTICS, INC.
Filing Type: Form 8-K (Current Report)
Filing Date: November 13, 2006
Reporting Period: This filing serves as a conduit for a press release dated November 9, 2006, reporting financial results for the three and nine months ended September 30, 2006.
Key Financial Metrics
The provided text is a cover document referencing a press release (Exhibit 99.1) containing the actual financial data. The text of this Form 8-K does not contain specific numerical values for:
- Revenue
- Profit or Net Loss
- Cash Flow
- Margins
- Debt or Liquidity positions
Note: Specific financial figures are not present in the source text provided.
Material Changes
The filing text does not provide specific details regarding material changes in financial condition or operations compared to prior periods. It only confirms the issuance of a press release containing these results.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It strictly references the attached press release for operational results.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 9, 2006) to obtain actual revenue, net loss, and cash position figures.
- Verify the specific operational milestones or clinical trial updates mentioned in the referenced press release.
- Confirm the company's cash runway and burn rate, as these are critical for a biotechnology firm but are not detailed in this cover document.